Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15422727 | 0.82 | SLC1A2 (0.33) | SLC1A2 | |
| SCHEMBL18020563 | 0.77 | SLC1A2 (0.45) | SLC1A2CYP2D6CYP2C9MEN1KMT2A | |
| SCHEMBL1564214 | 0.73 | KMT2A (0.53) | SLC1A2CYP2D6CYP2C9MEN1KMT2A | |
| SCHEMBL57078 | 0.73 | KMT2A (0.53) | SLC1A2CYP2D6CYP2C9MEN1KMT2A | |
| SCHEMBL9182487 | 0.71 | KMT2A (0.49) | SLC1A2CYP2D6CYP2C9MEN1KMT2A | |
| SCHEMBL29471924 | 0.71 | SLC1A2 (0.44) | SLC1A2CYP2D6CYP2C9MEN1KMT2A | |
| SCHEMBL4522866 | 0.69 | SLC1A2 (0.40) | SLC1A2CYP2D6CYP2C9MEN1KMT2A | |
| SCHEMBL3904196 | 0.69 | GLA (0.32) | — | |
| SCHEMBL5590839 | 0.68 | SLC1A2 (0.45) | SLC1A2MEN1KMT2AALDH1A1 | |
| Ethylene Glycol SCHEMBL3521351 | 0.67 | SLC1A2 (0.47) | SLC1A2CYP2D6CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 718 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035410-A1 | THERAPEUTIC PEPTIDES AND METHODS OF PEPTIDE DESIGN | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-02-05 | — | — | US | claimed |
| EP-4626462-A1 | GLUCOCEREBROSIDASE (GBA) POLYMER CONJUGATE, PREPARATION METHOD AND USE FOR NANOTECHNOLOGICAL BASED ENZYME REPLACEMENT THERAPY | Fundació Hospital Universitari Vall Hebron - Institut de Recerca (ES) | 2025-10-08 | — | — | EP | claimed |
| WO-2024115612-A1 | GLUCOCEREBROSIDASE (GBA) POLYMER CONJUGATE, PREPARATION METHOD AND USE FOR NANOTECHNOLOGICAL BASED ENZYME REPLACEMENT THERAPY | FUNDACIÓ HOSPITAL UNIVERSITARI VALL HEBRON - INSTITUT DE RECERCA (VHIR) (ES) | 2024-06-06 | — | — | WO | claimed |
| US-20230270882-A1 | PEPTIDE-NANOPARTICLE CONJUGATES | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-08-31 | — | — | US | claimed |
| US-11564995-B2 | Peptide-nanoparticle conjugates | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-01-31 | — | — | US | claimed |
| CN-115087465-A | Peptide-nanoparticle conjugates | 威斯康星校友研究基金会 | 2022-09-20 | — | — | CN | claimed |
| US-20210393799-A1 | DENDRITIC POLYMERS COMPLEXED WITH IMMUNE CHECKPOINT INHIBITORS FOR ENHANCED CANCER IMMUNOTHERAPY | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2021-12-23 | — | — | US | claimed |
| CN-113613680-A | Dendrimers complexed with immune checkpoint inhibitors for enhancing cancer immunotherapy | 威斯康星校友研究基金会 | 2021-11-05 | — | — | CN | claimed |
| US-11125713-B2 | Electrochemical sensor for analtye detection | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-09-21 | — | — | US | claimed |
| WO-2020092304-A9 | DENDRITIC POLYMERS COMPLEXED WITH IMMUNE CHECKPOINT INHIBITORS FOR ENHANCED CANCER IMMUNOTHERAPY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-07-22 | — | — | WO | claimed |
| WO-2010006604-A1 | HIGH CAPACITY SOLID PHASE | RADIOMETER MEDICAL APS (DK) | 2010-01-21 | — | — | WO | claimed |
| US-20100003701-A1 | COVALENT MODIFICATION AND CONJUGATION OF LUCIFERASE | CARDIOGENICS INC. (CA) | 2010-01-07 | — | — | US | claimed |
| EP-2054439-A1 | CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF | INSTITUT PASTEUR (FR) | 2009-05-06 | — | — | EP | claimed |
| WO-2008015273-A1 | CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF | INSTITUT PASTEUR (FR) | 2008-02-07 | — | — | WO | claimed |
| US-20070254311-A1 | Covalent modification and conjugation of luciferase | CARDIOGENICS INC. (CA) | 2007-11-01 | — | — | US | claimed |
| US-7067322-B2 | Fusion protein arrays on metal substrates for surface plasmon resonance imaging | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-06-27 | — | — | US | claimed |
| WO-2001040306-A9 | HUMAN ANTIBODIES AS DETECTION REAGENTS | BIOSITE DIAGNOSTICS INC (US) | 2002-05-30 | — | — | WO | claimed |
| EP-0341304-A4 | IMPROVED RICIN MOLECULES AND RICIN TOXIN CONJUGATES | — | 1991-01-30 | — | — | EP | claimed |
| EP-0341304-A1 | IMPROVED RICIN MOLECULES AND RICIN TOXIN CONJUGATES | GENETICS INSTITUTE, INC. (US) | 1989-11-15 | — | — | EP | claimed |
| WO-1989004839-A1 | IMPROVED RICIN MOLECULES AND RICIN TOXIN CONJUGATES | GENETICS INSTITUTE, INC. (US) | 1989-06-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035410-A1 | THERAPEUTIC PEPTIDES AND METHODS OF PEPTIDE DESIGN | MICA, IGSF11, TNFSF10 | SLC1A2 1535/4885CYP2D6 3754/4885CYP2C9 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.